Samir Agrawal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Samir Agrawal has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Mozid
Department of Cardiology, Leeds General Infirmary, Leeds, UK
1 shared publication Alberto Vega Hernández
1 shared publicationAleksandra Barac
1 shared publication- Aleksandra Barac
Emerging Infections Subcommittee, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
1 shared publication Alessandra Romano
1 shared publicationAlessia Di Pilla
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Open AccessTreatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- Open Access
Invasive Fungal Disease Associated With Targeted Agents for Acute Myeloid Leukaemia: A Systematic Review
Objective: To examine the incidence of invasive fungal disease (IFD) in patients receiving targeted agents for acute myeloid leukaemia (AML).Methods: Literature for this systematic review was identified through a PubMed search in April 2024, using AML, IFD and targeted therapy terms. The following filters were applied: published in the last 10 years and published in English.Results: The PubMed search yielded 54 results, of which 16 were deemed relevant for inclusion. Four additional references were identified through manual searches. The majority of publications focused on the incidence of IFD during treatment with targeted agents; the remainder focused on the efficacy of targeted treatments and reported IFD as an adverse event. Most publications were retrospective analyses. Prophylaxis use and agents differed across studies. In several studies, IFD incidence was above the 8% threshold identified for anti‐mould prophylaxis. Aspergillus was the most commonly reported pathogen, and most IFD cases occurred in the lungs.Conclusions: IFD is relatively common among patients with AML receiving targeted therapies, despite the use of prophylaxis. Prospective studies with detailed IFD reporting, together with large epidemiological studies, are required to better understand the risk factors for, and incidence and nature of IFD in this patient population.
Open AccessInvasive Fungal Disease Associated With Targeted Agents for Acute Myeloid Leukaemia: A Systematic Review
Objective: To examine the incidence of invasive fungal disease (IFD) in patients receiving targeted agents for acute myeloid leukaemia (AML).Methods: Literature for this systematic review was identified through a PubMed search in April 2024, using AML, IFD and targeted therapy terms. The following filters were applied: published in the last 10 years and published in English.Results: The PubMed search yielded 54 results, of which 16 were deemed relevant for inclusion. Four additional references were identified through manual searches. The majority of publications focused on the incidence of IFD during treatment with targeted agents; the remainder focused on the efficacy of targeted treatments and reported IFD as an adverse event. Most publications were retrospective analyses. Prophylaxis use and agents differed across studies. In several studies, IFD incidence was above the 8% threshold identified for anti‐mould prophylaxis. Aspergillus was the most commonly reported pathogen, and most IFD cases occurred in the lungs.Conclusions: IFD is relatively common among patients with AML receiving targeted therapies, despite the use of prophylaxis. Prospective studies with detailed IFD reporting, together with large epidemiological studies, are required to better understand the risk factors for, and incidence and nature of IFD in this patient population.
- 1 May 2014
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 9 (3) , 269-278
Safety and Feasibility of Intramyocardial Versus Intracoronary Delivery of Autologous Cell Therapy in Advanced Heart Failure: The REGENERATE-IHD Pilot Study
Aim: This study presents an interim safety and feasibility analysis of the REGENERATE-IHD randomized controlled trial, which is examining the safety and efficacy of three different delivery routes of bone marrow-derived stem cells (BMSCs) in patients with ischemic heart failure. Methods & results: The first 58 patients recruited to the REGENERATE-IHD study are included in this interim analysis (pilot). Symptomatic patients with ischemic heart failure were randomized to receive subcutaneous granulocyte colony-stimulating factor or saline injections only; or subcutaneous granulocyte colony-stimulating factor injections followed by intracoronary or intramyocardial injections of BMSCs or serum (control). No significant differences were found in terms of safety and feasibility between the different delivery routes, with no significant difference in procedural complications or major adverse cardiac events. There was a signal towards improved heart failure symptoms in the patients treated with intramyocardial in...
- 1 May 2014
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 9 (3) , 269-278
Safety and Feasibility of Intramyocardial Versus Intracoronary Delivery of Autologous Cell Therapy in Advanced Heart Failure: The REGENERATE-IHD Pilot Study
Aim: This study presents an interim safety and feasibility analysis of the REGENERATE-IHD randomized controlled trial, which is examining the safety and efficacy of three different delivery routes of bone marrow-derived stem cells (BMSCs) in patients with ischemic heart failure. Methods & results: The first 58 patients recruited to the REGENERATE-IHD study are included in this interim analysis (pilot). Symptomatic patients with ischemic heart failure were randomized to receive subcutaneous granulocyte colony-stimulating factor or saline injections only; or subcutaneous granulocyte colony-stimulating factor injections followed by intracoronary or intramyocardial injections of BMSCs or serum (control). No significant differences were found in terms of safety and feasibility between the different delivery routes, with no significant difference in procedural complications or major adverse cardiac events. There was a signal towards improved heart failure symptoms in the patients treated with intramyocardial in...
- Open Access
- 19 November 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (21) , 3480
A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report.
Abstract 3480
- 19 November 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (21) , 3480
Open AccessA Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report.
Abstract 3480